Your browser doesn't support javascript.
loading
In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.
Pearson, Ryan M; Casey, Liam M; Hughes, Kevin R; Miller, Stephen D; Shea, Lonnie D.
Afiliación
  • Pearson RM; Department of Biomedical Engineering, University of Michigan, 1119 Carl A. Gerstacker Building, 2200 Bonisteel Boulevard, Ann Arbor, MI 48109-2099, USA.
  • Casey LM; Department of Chemical Engineering, University of Michigan, 2300 Hayward Ave., Ann Arbor, MI 48105, USA.
  • Hughes KR; Department of Biomedical Engineering, University of Michigan, 1119 Carl A. Gerstacker Building, 2200 Bonisteel Boulevard, Ann Arbor, MI 48109-2099, USA.
  • Miller SD; Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, 6-713 Tarry Building, 303 E. Chicago Avenue, Chicago, IL 60611, USA; Chemistry of Life Processes Institute (CLP), Northwestern University, Evanston, IL 60208, USA; The Robert H. Lurie Comprehensive Cancer Ce
  • Shea LD; Department of Biomedical Engineering, University of Michigan, 1119 Carl A. Gerstacker Building, 2200 Bonisteel Boulevard, Ann Arbor, MI 48109-2099, USA; Department of Chemical Engineering, University of Michigan, 2300 Hayward Ave., Ann Arbor, MI 48105, USA. Electronic address: ldshea@umich.edu.
Adv Drug Deliv Rev ; 114: 240-255, 2017 05 15.
Article en En | MEDLINE | ID: mdl-28414079
ABSTRACT
Technologies that induce antigen-specific immune tolerance by mimicking naturally occurring mechanisms have the potential to revolutionize the treatment of many immune-mediated pathologies such as autoimmunity, allograft rejection, and allergy. The immune system intrinsically has central and peripheral tolerance pathways for eliminating or modulating antigen-specific responses, which are being exploited through emerging technologies. Antigen-specific tolerogenic responses have been achieved through the functional reprogramming of antigen-presenting cells or lymphocytes. Alternatively, immune privileged sites have been mimicked using biomaterial scaffolds to locally suppress immune responses and promote long-term allograft survival. This review describes natural mechanisms of peripheral tolerance induction and the various technologies being developed to achieve antigen-specific immune tolerance in vivo. As currently approved therapies are non-specific and carry significant associated risks, these therapies offer significant progress towards replacing systemic immune suppression with antigen-specific therapies to curb aberrant immune responses.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Terapia de Inmunosupresión / Tolerancia Inmunológica / Antígenos Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Terapia de Inmunosupresión / Tolerancia Inmunológica / Antígenos Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2017 Tipo del documento: Article